Management of Vancomycin and Linezolid in HIV Patients

Introduction to Antibiotic Use in HIV Patients

• The American College of Physicians recommends that most antibiotics, including vancomycin and linezolid, can be safely administered with antiretroviral therapy, but specific drug-drug interactions must be carefully evaluated before prescribing 2

Pharmacodynamic Properties

• Vancomycin exhibits concentration-independent killing, making it fundamentally different from concentration-dependent antibiotics 1

Drug-Drug Interactions with Antiretroviral Therapy

• Vancomycin does not undergo significant hepatic metabolism via CYP450 enzymes, avoiding the major interaction pathway that affects many other drugs used with protease inhibitors or NNRTIs 3, 4
• The Centers for Disease Control and Prevention recommends regular monitoring of renal function when vancomycin is used with tenofovir disoproxil fumarate due to additive nephrotoxicity risk 2

Clinical Management Recommendations

• Vancomycin is preferred when patients are on zidovudine-containing ART regimens to avoid additive myelosuppression 1, 5
• The National Comprehensive Cancer Network recommends monitoring platelet counts after initiation of linezolid, particularly after 7.5 days of treatment 1
• The Infectious Diseases Society of America recommends avoiding linezolid with zidovudine due to myelosuppression 1, 5

Special Populations

• The American College of Physicians recommends consultation with an HIV specialist, HIV pharmacist, and oncology pharmacist when managing complex drug-drug interactions 1, 5
• The National Institutes of Health recommends avoiding didanosine and stavudine with linezolid due to additive peripheral neuropathy risk 1

Common Pitfalls to Avoid

• The World Health Organization recommends never discontinuing ART during antibiotic therapy unless absolutely necessary due to risk of immunologic compromise and opportunistic infections 6, 1